原发性肝癌是全球范围内高发病率且高致死率的恶性肿瘤之一。在原发性肝癌治疗中，单一药物往往受到不良反应和耐药性的限制，联合用药可以发挥多机制协同作用增加疗效，降低毒副作用，延缓耐药性。中药单体具有良好的抗肝癌作用，较低的毒副作用以及可以拮抗化疗药物对正常组织细胞的损害等优点常被用于与化疗药物联合应用治疗肝癌。纳米制剂可以使联合使用的药物在吸收分布上呈现出同步性，更好地发挥联用药物的协同作用，常被用于联用药物的负载和递送。对化疗药物联合中药单体的优势、纳米共载的优势以及用于肝癌治疗的中药单体与化疗药物共载纳米制剂研究进展进行了综述，为联合用药抗肝癌的研究提供参考。

Primary liver cancer is one of the malignant tumors with high incidence and mortality rates worldwide. In its treatment, single-drug therapies are often limited by toxic side effects and drug resistance. Combination therapy can exert multi-mechanism synergistic effects to enhance efficacy, reduce toxic side effects, and delay the development of drug resistance. Traditional Chinese medicine (TCM) monomers, which exhibit potent anti-liver cancer activity, lower toxicity, and the ability to counteract chemotherapy-induced damage to normal tissues, are frequently used in combination with chemotherapeutic drugs for liver cancer treatment. Nano-formulations enable synchronized absorption and distribution of combined drugs, thereby enhancing their synergistic effects, and are widely used for the loading and delivery of co-administered drugs. This article reviews the advantages of combining chemotherapeutic drugs with TCM monomers, the benefits of nano co-delivery, and recent research progress in co-delivery nano-formulations of TCM monomers and chemotherapeutic drugs for liver cancer treatment, aiming to provide insights for advancing research on combination therapy against liver cancer.

R286.2

广西自然科学基金资助项目（2022GXNSFDA035063）；广西自然科学基金资助项目（2023GXNSFAA026366）；国家自然科学基金资助项目（82360818）；国家自然科学基金资助项目（81960756）